Program
shingrix
Also written as “Herpes Zoster Vaccine GSK1437173A”, “Shingrix” and “Herpes Zoster vaccine GSK 1437173A”.
In GlaxoSmithKline's pipeline, Recombinant protein, adjuvanted vaccine
. Its studies are mostly in Herpes Zoster · Cardiovascular Diseases · Respiratory Syncytial Virus Infections · Respiration Disorders, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 293 open or running | phase 4since Mar 25, 2026 | Feb 12, 2007 | Aug 23, 2027phase 3 · NCT05371080 |
| Wuhan BravoVax | 10 open or running | phase 1since Jan 28, 2023 | Jan 28, 2023 | none ahead |
- Named in GlaxoSmithKline’s own pipeline as
GSK1437173
, phase 3, as of Sep 30, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 16 studies since Feb 12, 2007.
- Feb 16, 2016Phase 3 study in Herpes ZosterGlaxoSmithKline · NCT02690207 · 8,687 enrolled · United States, Australia, Brazil and more
- Mar 10, 2016Phase 3 study in Herpes ZosterGlaxoSmithKline · NCT02723773 · 7,539 enrolled · United States, Australia, Brazil and more
- Apr 7, 2016Phase 3 study in Herpes ZosterGlaxoSmithKline · NCT02735915 · 70 enrolled · Czechia, Germany, Sweden
- Nov 29, 2016Phase 3 study in Herpes ZosterGlaxoSmithKline · NCT02979639 · 404 enrolled · United States
- Feb 12, 2018Phase 3 study in Herpes ZosterGlaxoSmithKline · NCT03439657 · 913 enrolled · United States, Canada, Estonia and more
- Mar 27, 2019Phase 2 study in Respiration DisordersGlaxoSmithKline · NCT03894969 · 541 enrolled · Estonia, Finland, France and more
- Sep 3, 2019Phase 3 study in Herpes ZosterGlaxoSmithKline · NCT04091451 · 1,430 enrolled · Russia
- Nov 22, 2019Phase 3 study in Herpes ZosterGlaxoSmithKline · NCT04176939 · 68 enrolled · Belgium, Canada, Finland and more
- Jan 21, 2022Phase 3 study in Herpes ZosterGlaxoSmithKline · NCT05219253 · 288 enrolled · India
- May 9, 2022Phase 3 study in Herpes ZosterGlaxoSmithKline · NCT05371080 · 3,038 enrolled · United States, Australia, Brazil and more
- Jan 28, 2023Wuhan BravoVax's first study: phase 1 study in Herpes ZosterNew to Wuhan BravoVaxWuhan BravoVax · NCT05718037 · 40 enrolled
- Jul 21, 2023Phase 3 study in Respiratory Syncytial Virus InfectionsGlaxoSmithKline · NCT05966090 · 530 enrolled · United States, Canada
- Mar 25, 2026Phase 4 study in Herpes ZosterGlaxoSmithKline · NCT07502560 · 33,609 planned · Finland
- Oct 7, 2026Phase 3 study in Cardiovascular DiseasesGlaxoSmithKline · NCT07872046 · 16,390 planned
Ahead
- Aug 23, 2027Primary completion: phase 3 study in Herpes ZosterGlaxoSmithKline · NCT05371080
- Apr 1, 2030Primary completion: phase 4 study in Herpes ZosterGlaxoSmithKline · NCT07502560
- Nov 25, 2032Primary completion: phase 3 study in Cardiovascular DiseasesGlaxoSmithKline · NCT07872046
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Recombinant protein, adjuvanted vaccine”the company's pipeline, read by Claude · source
“A recombinant, subunit herpes zoster (HZ) vaccine containing varicella-zoster virus (VZV) glycoprotein E (gE), that can potentially be used to prevent HZ infection, also called shingles. Upon administration, zoster vaccine recombinant, adjuvanted stimulates the host immune system to induce both s…”NCIt, read by Claude
“Envelope glycoprotein E vaccine antigen”ChEMBL 37, by rule
Studies
All 30 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07872046Cardiovascular Diseases | 3 | Not yet recruiting | GlaxoSmithKline | Nov 25, 2032 | 16,390 |
| NCT07502560Herpes Zoster · Finland | 4 | Recruiting | GlaxoSmithKline | Apr 1, 2030 | 33,609 |
| NCT05966090Respiratory Syncytial Virus Infections · United States, Canada | 3 | Completed | GlaxoSmithKline | Feb 19, 2024 | 530 |
| NCT05718037Herpes Zoster | 1 | UNKNOWN | Wuhan BravoVax | Jan 31, 2024 | 40 |
| NCT05371080Herpes Zoster · United States, Australia, Brazil and more | 3 | Active, not recruiting | GlaxoSmithKline | Aug 23, 2027 | 3,038 |
| NCT05219253Herpes Zoster · India | 3 | Completed | GlaxoSmithKline | Oct 11, 2022 | 288 |
| NCT04176939Herpes Zoster · Belgium, Canada, Finland and more | 3 | Completed | GlaxoSmithKline | Aug 12, 2022 | 68 |
| NCT04091451Herpes Zoster · Russia | 3 | Completed | GlaxoSmithKline | Feb 15, 2024 | 1,430 |
| NCT03894969Respiration Disorders · Estonia, Finland, France and more | 2 | Completed | GlaxoSmithKline | Aug 31, 2020 | 541 |
| NCT03439657Herpes Zoster · United States, Canada, Estonia and more | 3 | Completed | GlaxoSmithKline | May 6, 2019 | 913 |
| NCT02979639Herpes Zoster · United States | 3 | Completed | GlaxoSmithKline | Apr 12, 2017 | 404 |
| NCT02735915Herpes Zoster · Czechia, Germany, Sweden | 3 | Completed | GlaxoSmithKline | Aug 28, 2017 | 70 |
| NCT02723773Herpes Zoster · United States, Australia, Brazil and more | 3 | Completed | GlaxoSmithKline | Jun 28, 2023 | 7,539 |
| NCT02690207Herpes Zoster · United States, Australia, Brazil and more | 3 | Completed | GlaxoSmithKline | Mar 15, 2019 | 8,687 |
| NCT02581410Herpes Zoster · United States | 3 | Completed | GlaxoSmithKline | Aug 30, 2016 | 430 |
| NCT02058589Herpes Zoster · Belgium, Canada, Czechia and more | 3 | Completed | GlaxoSmithKline | May 11, 2016 | 265 |
| NCT02052596Herpes Zoster · United States | 3 | Completed | GlaxoSmithKline | Jun 16, 2015 | 935 |
| NCT02045836Herpes Zoster · United States, Canada, Estonia | 3 | Completed | GlaxoSmithKline | Jul 2, 2015 | 865 |
| NCT01954251Herpes Zoster · United States, Canada, Germany | 3 | Completed | GlaxoSmithKline | Jun 2, 2014 | 829 |
| NCT01798056Herpes Zoster · Canada, Czechia, France and more | 3 | Completed | GlaxoSmithKline | Jun 18, 2015 | 237 |
| NCT01777321Herpes Zoster · Japan | 3 | Completed | GlaxoSmithKline | Oct 10, 2013 | 60 |
| NCT01751165Herpes Zoster · United States, Estonia | 3 | Completed | GlaxoSmithKline | May 22, 2014 | 354 |
| NCT01610414Herpes Zoster · United States, Australia, Belgium and more | 3 | Completed | GlaxoSmithKline | Nov 4, 2016 | 1,877 |
| NCT01165229Herpes Zoster · United States, Australia, Brazil and more | 3 | Completed | GlaxoSmithKline | Jul 24, 2015 | 14,819 |
| NCT01165203Herpes Zoster · United States, Germany, United Kingdom | 2 | Completed | GlaxoSmithKline | Jul 6, 2012 | 123 |
| NCT01165177Herpes Zoster · United States, Australia, Brazil and more | 3 | Completed | GlaxoSmithKline | May 9, 2014 | 16,165 |
| NCT01086449Herpes Zoster · Australia | 1 | Completed | GlaxoSmithKline | Jun 25, 2010 | 20 |
| NCT00920218Herpes Zoster · United States | 2 | Completed | GlaxoSmithKline | Apr 26, 2011 | 121 |
| NCT00802464Herpes Zoster · United States, Czechia, Spain | 2 | Completed | GlaxoSmithKline | Jul 2, 2010 | 410 |
| NCT00434577Herpes Zoster · Czechia, Germany, Netherlands and more | 2 | Completed | GlaxoSmithKline | Oct 4, 2007 | 715 |
How it is read
Names in the registry
- “Herpes Zoster Vaccine GSK1437173A”, 6 entries
- “Shingrix”, 3 entries
- “Herpes Zoster vaccine GSK 1437173A”, 3 entries
- “Herpes zoster vaccine GSK1437173A”, 3 entries
- “HZ/su vaccine”, 2 entries
Conditions, from the studies’ own filings
- Herpes Zoster, 29 studies
- Cardiovascular Diseases, 1 study
- Respiratory Syncytial Virus Infections, 1 study
- Respiration Disorders, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.